Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.

Choi, Yunsik; Lee, Sanghyuk; Kim, Kapyoul; Kim, Soo-Hyun; Chung, Yeun-Jun; Lee, Charles
Experimental & molecular medicine
2018Aug ; 50 ( 8 ) :99.
PMID : 30089794
ÀúÀÚ »ó¼¼Á¤º¸
Choi, Yunsik -
Lee, Sanghyuk -
Kim, Kapyoul -
Kim, Soo-Hyun -
Chung, Yeun-Jun -
Lee, Charles -
ABSTRACT
Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient's own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.
na
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This study described human microbiota-associated mice developed that are established from germ-free mice by fecal microbiota transplantation.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1038/s12276-018-0115-0
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå